Shamim Ruff Net Worth

The estimated Net Worth of Shamim Ruff is at least $2 Milion dollars as of 28 July 2023. Shamim Ruff owns over 8,235 units of Sarepta Therapeutics Inc stock worth over $2,002,114 and over the last 8 years Shamim sold SRPT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Shamim Ruff SRPT stock SEC Form 4 insiders trading

Shamim has made over 8 trades of the Sarepta Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Shamim exercised 8,235 units of SRPT stock worth $759,267 on 28 July 2023.

The largest trade Shamim's ever made was exercising 12,138 units of Sarepta Therapeutics Inc stock on 20 July 2017 worth over $168,840. On average, Shamim trades about 3,075 units every 132 days since 2016. As of 28 July 2023 Shamim still owns at least 15,594 units of Sarepta Therapeutics Inc stock.

You can see the complete history of Shamim Ruff stock trades at the bottom of the page.

What's Shamim Ruff's mailing address?

Shamim's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry oraz M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.

What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.

Complete history of Shamim Ruff stock trades at Reata Pharmaceuticals Inc i Sarepta Therapeutics Inc

Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Gilmore O'Neill,
  Executive Vice President, R&D and Chief Medical Officer
• William Ciambrone,
  Executive Vice President - Technical Operations
• David Howton,
  Executive Vice President, General Counsel, Secretary
• Alexander Cumbo,
  Executive Vice President and Chief Commercial Officer
• Douglas Ingram,
  President, Chief Executive Officer, Director
• Douglas S. Ingram,
  Pres, CEO & Director
• Dr. Gilmore O'Neill M.D.,
  Exec. Officer
• Dr. Louise Rodino-Klapac Ph.D.,
  Chief Scientific Officer and Head of R&D
• Ian Michael Estepan,
  Exec. VP & CFO
• William F. Ciambrone,
  Exec. VP of Technical Operations
• M. Kathleen Behrens,
  Independent Chairwoman of the Board
• Richard Barry,
  Independent Director
• Hans Wigzell,
  Independent Director
• Claude Nicaise,
  Independent Director
• Mary Gray,
  Independent Director
• John Martin,
  Independent Director
• Joseph Bratica,
  Interim Principal Financial and Accounting Officer
• Dr. Diane L. Berry,
  Sr. VP of Global Health Policy and Gov. & Patient Affairs
• Alison Nasisi,
  Chief People Officer & VP
• Ryan E. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Mary Jenkins,
  Sr. Mang. of Investor Relations
• Michael W Bonney,
  Director
• Ben Gil Price,
  Director
• Catherine Stehman Breen,
  SVP, Chief Medical Officer
• Jayant Aphale,
  SVP Technical Operations
• Jean Paul Kress,
  Director
• William Alden Goolsbee,
  Director
• Shamim Ruff,
  SVP, Chief Regulatory Affairs
• Sandesh Mahatme,
  EVP, CFO & CBO
• Guriqbal S. Basi,
  SVP, Chief Scientific Officer
• Michael A Jacobsen,
  VP of Finance and PAO
• Anthony Martignetti,
  
• Nishan Garabedian Christopher,
  President and CEO
• Anthony R Chase,
  Director
• John Hodgman,
  Director
• Arthur M Krieg,
  SVP, Chief Scientific Officer
• Edward M. Md Kaye,
  SVP & Chief Medical Officer
• Ian Michael Estepan,
  Chief Financial Officer
• Ryan Edward Brown,
  EVP, General Counsel
• Louise Rodino Klapac,
  Head of R&D, CSO
• Bilal Arif,
  Chief Tech Ops Officer
• Stephen Mayo,
  
• Kathryn Jean Boor,
  
• Dallan Murray,
  Chief Customer Officer